超凡国际

    Stock code: 002653.SZ

    Innovation-driven Pipeline

    The Company has more than 20 Class 1 innovative drug projects in clinical development across anesthesia and analgesia, respiratory diseases, chronic metabolic diseases, autoimmune diseases, oncology, and digestive and hepatic diseases. Five Class 1 innovative drugs are moving rapidly toward commercialization.
    Anesthesia/Analgesia Autoimmune Diseases Chronic Diseases Autoimmune Disease Oncology Others

    Sishuning®

    Sishuning® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Sedation and anesthesia for non-intubatedsurgeries/procedures

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishuning® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Induction and maintenance of general anesthesia

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishuning® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Sedation during mechanical ventilationin intensive care

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishuning® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Pediatric indications (China)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishuning® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Adult General Anesthesia Induction (U.S.)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Simeining®

    Simeining® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Diabetic Peripheral Neuropathic Pain (DPNP)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Simeining® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Post Herpetic Neuralgia (PHN)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Simeining® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Central Nervous System Analgesia

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishujing®

    Sishujing® (HSK21542 Injection)

    Target: Peripheral kappa-opioid receptor (KOR)

    Abdominal surgery postoperative pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    Sishujing® (HSK21542 Injection)

    Target: Peripheral kappa-opioid receptor (KOR)

    Orthopedic Analgesia

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK36357

    HSK36357

    Target: AAK1

    Neuropathic Pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK55718

    HSK55718

    Target: Nav1.8

    Acute Pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK51155

    HSK51155

    Target: Nav1.8

    Migraine / Acute Pain / Chronic Pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched